Akums Drugs and Pharmaceuticals gains on reporting consolidated net profit of Rs 75.14 crore in Q4
Akums Drugs & Pharmaceuticals is currently trading at Rs. 585.60, up by 3.55 points or 0.61% from its previous closing of Rs. 582.05 on the BSE.
The scrip opened at Rs. 596.00 and has touched a high and low of Rs. 620.00 and Rs. 585.00 respectively. So far 90388 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 2 has touched a 52 week high of Rs. 1174.85 on 20-Aug-2024 and a 52 week low of Rs. 407.40 on 07-Apr-2025.
Last one week high and low of the scrip stood at Rs. 620.00 and Rs. 556.00 respectively. The current market cap of the company is Rs. 9254.77 crore.
The promoters holding in the company stood at 75.26%, while Institutions and Non-Institutions held 13.17% and 11.58% respectively.
Akums Drugs and Pharmaceuticals has reported net profit of Rs 27.59 crore for fourth quarter ended March 31, 2025 as compared to net loss of Rs 57.87 crore for the same quarter in the previous year. The total income of the company increased by 11.01% at Rs 360.80 crore for Q4FY25 as compared to Rs 325.02 crore for the corresponding quarter previous year.
On consolidated basis, the company has reported net profit of Rs 75.14 crore for fourth quarter ended March 31, 2025 as compared to net loss of Rs 32.88 crore for the same quarter in the previous year. The total income of the company increased by 12.43% at Rs 1073.09 crore for Q4FY25 as compared to Rs 954.45 crore for the corresponding quarter previous year.
For the year ended March 31, 2025, the company has reported net profit of Rs 161.00 crore as compared to net loss of Rs 165.45 crore for the previous year. However, total income of the company decreased by 6.65% at Rs 1435.98 crore for year under review as compared to Rs 1538.24 crore for year ended March 31, 2024.
For the year ended March 31, 2025, on the consolidated basis, the company has reported net profit of Rs 345.25 crore as compared to net loss of Rs 45.28 crore for the previous year. However, total income of the company decreased by 1% at Rs 4170.28 crore for year under review as compared to Rs 4212.21 crore for year ended March 31, 2024.
